Bayer Asundexian Trial Results Boost Shares

Bayer asundexian trial results lifted shares after Phase III met endpoints without extra major bleeding, prompting investors to reprice the pharma unit.

November 24, 2025·2 min read
View all news articles
Flat vector pill and vial icon symbolizing Bayer asundexian trial results and the drug's clinical and market shift

KEY TAKEAWAYS

  • OCEANIC-STROKE Phase III cut recurrent ischemic stroke risk without increasing ISTH major bleeding.
  • Shares rose 8% to 11% following the topline results as investors repriced Bayer's pharma outlook.
  • Bayer will engage regulators globally and present full data at an upcoming scientific congress.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

On Nov. 23, 2025, Bayer AG (BAYRY) reported that its investigational anticoagulant asundexian significantly lowered the risk of recurrent ischemic stroke without increasing major bleeding. The positive Phase III results reversed earlier setbacks and boosted confidence in Bayer’s pharmaceutical division.

Trial Results and Design

Bayer said in a press release that the OCEANIC-STROKE trial was a Phase III, multicenter, randomized, double-blind, placebo-controlled, event-driven study. It enrolled more than 12,300 patients who recently experienced non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. All participants received antiplatelet therapy.

The trial compared asundexian 50 mg once daily plus antiplatelet therapy against placebo plus antiplatelet therapy. Bayer reported a statistically significant reduction in recurrent ischemic stroke with no increase in major bleeding, as defined by the International Society on Thrombosis and Haemostasis (ISTH). This marks the first successful Phase III study in the Factor XIa inhibitor drug class.

Christian Rommel, head of research and development at Bayer Pharmaceuticals, said in the release, “We are excited by these positive topline findings which highlight the potential of Factor XIa inhibition as a new way to help protect patients from a recurrent stroke.”

Market Reaction and Outlook

Shares rose between 8% and 11% following the trial news, reflecting renewed investor confidence in Bayer’s drug pipeline. Analysts described the topline results as a material de-risking event and cited blockbuster potential, with some projecting annual sales in the billions.

The results reverse a 2023 setback when Bayer halted the OCEANIC-AF trial in atrial fibrillation after asundexian showed inferior efficacy compared with apixaban. Asundexian holds FDA Fast Track designation for stroke prevention after non-cardioembolic ischemic stroke but is not yet approved in any country.

Bayer said it will engage health authorities worldwide to prepare marketing authorization submissions. Detailed trial data will be presented at an upcoming scientific congress.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Netflix Earnings Send NFLX Stock Lower

Netflix Earnings Send NFLX Stock Lower

Netflix earnings for Q1 2026 beat forecasts but weak Q2 guidance and Reed Hastings' planned June exit pushed shares lower in after-hours trading.

Anthropic Mythos Rolls Out to Banks Amid Cyber Scrutiny

Anthropic Mythos Rolls Out to Banks Amid Cyber Scrutiny

Anthropic Mythos limited Glasswing rollout to banks prompted regulator scrutiny and raised cyber and operational risk, complicating bank positioning.

Spirit Airlines Liquidation Looms as Fuel Costs Surge

Spirit Airlines Liquidation Looms as Fuel Costs Surge

Spirit Airlines liquidation risk rises as jet fuel may exceed year-end cash, prompting creditors' doubts and forcing traders to reassess credit exposure.

AMD Stock Rises on Bernstein Raise and AI Demand

AMD Stock Rises on Bernstein Raise and AI Demand

AMD stock rose after Bernstein raised its 12-month target as record EPYC and MI300 data-center demand boosted flows ahead of May 5 Q1 2026 earnings.

Anthropic Claude Opus 4.7 Launches to General Availability

Anthropic Claude Opus 4.7 Launches to General Availability

Anthropic Claude Opus 4.7 went general; pricing stayed unchanged and Mythos stayed gated, a setup that could shift cloud AI costs and investor positioning.

Abbott Earnings Beat After Exact Sciences Deal

Abbott Earnings Beat After Exact Sciences Deal

Abbott earnings posted revenue and adjusted-profit beats but narrowed FY EPS guidance after the Exact Sciences acquisition, likely pressuring shares.